Want to see CASIF full AI Analyst Report?
CASI Pharmaceuticals (CASIF) AI Stock Analysis
Top Page
CASI Pharmaceuticals
(Other OTC:CASIF)
The score is weighed down primarily by very weak financial performance (declining revenue, large ongoing losses, persistent cash burn) and heightened balance-sheet risk from negative equity. Technical indicators are mixed but lean bearish due to the price trading below key longer-term moving averages and a negative MACD. Valuation provides limited support because the company is loss-making (negative P/E) and no dividend yield is available.
CASI Pharmaceuticals (CASIF) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $2.67M
- Dividend Yield
- ―
- Average Volume (3M)
- 2,566
- Price to Earnings (P/E)
- -0.1
- Beta (1Y)
- 1.24
- Revenue Growth
- -27.42%
- EPS Growth
- -6.12%
- Country
- US
- Employees
- 214
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
CASI Pharmaceuticals Business Overview & Revenue Model
Company Description
CASI Pharmaceuticals, Inc. operates as a biopharmaceutical firm, focusing on the development and commercialization of therapeutic and pharmaceutical products across the People's Republic of China, the United States, and international territories. The...
How the Company Makes Money
CASI generates revenue primarily from product sales of its commercial pharmaceutical products in its target markets (notably China), selling to hospitals, pharmacies, and other healthcare channels through its commercial organization and distribution...
CASI Pharmaceuticals Financial Statement Overview
Summary
Weak fundamentals: revenue has declined for three straight years and losses remain extreme (very large negative EBIT and net margins). The balance sheet is a key risk with stockholders’ equity turning negative in 2025 alongside higher debt, reducing financial flexibility and raising dilution/refinancing risk. Cash flow is consistently negative, indicating ongoing reliance on external funding despite some improvement in 2025 cash burn versus 2024.
Income Statement
18Very NegativeBalance Sheet
12Very NegativeCash Flow
16Very Negative| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 20.11M | 20.71M | 28.54M | 33.88M | 43.11M | 30.17M |
| Gross Profit | 12.06M | 10.06M | 11.15M | 20.05M | 27.28M | 17.61M |
| EBITDA | -38.75M | -43.77M | -34.87M | -21.54M | -35.79M | -33.40M |
| Net Income | -43.96M | -48.06M | -39.26M | -26.94M | -41.01M | -36.65M |
Balance Sheet | ||||||
| Total Assets | 21.06M | 25.65M | 53.67M | 75.27M | 96.23M | 138.30M |
| Cash, Cash Equivalents and Short-Term Investments | 3.77M | 5.63M | 16.09M | 30.77M | 51.34M | 48.57M |
| Total Debt | 40.50M | 27.49M | 22.14M | 21.24M | 1.34M | 4.33M |
| Total Liabilities | 79.33M | 62.93M | 51.82M | 51.10M | 29.30M | 30.34M |
| Stockholders Equity | -58.27M | -37.28M | 1.85M | 24.16M | 44.57M | 84.50M |
Cash Flow | ||||||
| Free Cash Flow | 0 | -20.77M | -29.46M | -22.21M | -26.70M | -42.34M |
| Operating Cash Flow | 0 | -20.75M | -29.22M | -19.97M | -21.09M | -26.84M |
| Investing Cash Flow | 0 | 951.00K | 11.24M | -9.67M | 31.16M | -20.69M |
| Financing Cash Flow | 0 | 11.25M | 15.43M | -907.00K | -3.27M | 29.64M |
CASI Pharmaceuticals Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CASIF, the sentiment is Positive. The current price of 0.13 is above the 20-day moving average (MA) of 0.10, above the 50-day MA of 0.12, and below the 200-day MA of 0.24, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 66.17 is Neutral, neither overbought nor oversold. The STOCH value of 47.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CASIF.
CASI Pharmaceuticals Risk Analysis
CASI Pharmaceuticals disclosed 49 risk factors in its most recent earnings report. CASI Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksCASI Pharmaceuticals Peers Comparison
Overall Rating
MBRX46Neutral
MBIO43Neutral
CNSP42Neutral- CASIF42Neutral
SNTI38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| MBRX | 46Neutral | $8.29M | -0.02 | -816.56% | ― | ― | 85.06% |
| MBIO | 43Neutral | $3.03M | -0.89 | -34.23% | ― | ― | 85.52% |
| CNSP | 42Neutral | $7.31M | -0.21 | -204.25% | ― | ― | 88.43% |
| CASIF | 42Neutral | $2.67M | -0.06 | 96.40% | ― | -27.42% | -6.12% |
| SNTI | 38Underperform | $5.14M | -0.09 | -1539.97% | ― | ― | 80.28% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CASIF | Casi Pharmaceuticals, Inc. | 0.13 | -1.26 | -90.65% | |
| MBRX | Moleculin Biotech | 7.90 | -251.95 | -96.96% | |
| MBIO | Mustang Bio | 0.40 | -0.99 | -71.22% | |
| GNPX | Genprex | 2.24 | -114.36 | -98.08% | |
| CNSP | Cns Pharmaceuticals, Inc. | 5.00 | -2.17 | -30.26% | |
| SNTI | Senti Biosciences, Inc. | 0.17 | -1.83 | -91.75% |
CASI Pharmaceuticals Corporate Events
CASI Pharmaceuticals Nets $5.9 Million From Sale of Alesta Stake to BioMarin
On August 31, 2026, CASI Pharmaceuticals sold its equity interests in Alesta Therapeutics B.V. to BioMarin Pharmaceutical Inc. as part of BioMarin’s acquisition of Alesta. The deal delivered approximately US$5.9 million in net cash proceeds to...
CASI Pharmaceuticals Posts First-Half 2026 Results, Advances CID-103 After Nasdaq Delisting
CASI Pharmaceuticals reported its first-half 2026 business and financial results on August 14, highlighting progress with its lead antibody CID-103, including first patient dosing in a Phase 1/2 renal allograft AMR trial in China and completion of do...
CASI Pharmaceuticals Continues U.S. Streamlining With Senior Vice President Departure
On August 13, 2026, CASI Pharmaceuticals reported that Senior Vice President Wei (Larry) Zhang will no longer serve in his role at the company. The move is part of CASI’s previously announced initiative to streamline its U.S. branches, personne...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 30, 2026